GlassScriptPhysician profile
Qamar R Khan
NPI 1407026420
$1,548.79
in general payments reported to CMS, 2019-2025
27 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $240 · 2021: $270 · 2022: $310 · 2023: $251 · 2024: $194 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $504.28 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Pfizer INC. | $202.71 | 2019-2021 | |
| Boston Scientific Corporation | $90.03 | 2022-2025 | Wavewriter Alpha Prime 16, Avvigo Guidance System |
| Abbvie INC. | $89.17 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.36 | 2022-2025 | Relistor, Trulance |
| Allergan, INC. | $83.45 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $45.93 | 2024-2025 | |
| Nevro Corp. | $44.80 | 2020-2023 | Senza |
| Almatica Pharma LLC | $40.22 | 2021 | |
| Bioventus LLC | $36.83 | 2019-2020 | |
| Lilly USA, LLC | $33.67 | 2019-2020 | |
| Grt US Holding, INC. | $32.95 | 2021-2022 | |
| Depuy Synthes Sales INC. | $30.01 | 2022 | |
| Medtronic USA, INC. | $28.71 | 2020 | |
| Ferring Pharmaceuticals INC. | $25.77 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $22.34 | 2021 | |
| Abbott Laboratories | $21.62 | 2023 | Proclaim |
| Spr Therapeutics, INC | $17.62 | 2021 | |
| Amgen INC. | $15.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.13 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.58 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.44 | 2020 | |
| Zyla Life Sciences, INC. | $12.39 | 2019 | |
| Eisai INC. | $12.37 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $10.89 | 2019 | |
| Stratus Medical, LLC | $7.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qamar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.